Kolon TissueGene (950160) closed limit down on the Korea Exchange (KRX) regular session on the 21st, following the fallout from the announcement of top-line results from its U.S. Phase 3 clinical trial. With market investor sentiment sharply contracting, attention is focused on whether bargain-hunting buyers will step in during the 22nd session or whether further selling will continue.

Closes Limit Down… Selling Pressure Dominates Throughout the Session

On this day, Kolon TissueGene closed at 42,900 won, plunging 18,300 won (29.90%) from the previous trading day. Immediately after the market opened, strong selling pressure flooded in, pushing the price down to the limit, and it ultimately finished trading at the limit-down price. On the same day, the KOSDAQ market showed a relatively stable trend, rising 3.70 points (0.49%) to 753.34 from the previous trading day, but Kolon TissueGene moved in the opposite direction of the broader market due to company-specific negative news.

TG-C 15302 Study Falls Short of Statistical Significance on Primary Endpoint

The direct cause of the plunge was the top-line results of the 'TG-C 15302 Study,' part of the Phase 3 clinical program for the osteoarthritis treatment TG-C, which the company disclosed. The study failed to achieve statistical significance on its pre-specified primary endpoint. However, the company explained that no serious safety concerns were observed during the clinical trial, and additional analysis of the detailed data is currently underway.

Not a Discontinuation of Development… TG-C 12301 Study Top-Line Results Scheduled for October

Kolon TissueGene emphasized that these results do not mean the end of TG-C development. Another pivotal study in the Phase 3 program, the TG-C 12301 Study, is proceeding as planned, with top-line data scheduled to be released in October. The company stated that it will formulate its future development strategy by comprehensively analyzing the results of both studies and review the optimal development direction, including consultations with regulatory authorities. The company also noted that it maintains its existing assessment of the therapeutic value TG-C can offer to patients with knee osteoarthritis.

In a press briefing, Kolon TissueGene CEO Jeon Seung-ho stated, "Given that the efficacy exceeded our expectations, I consider this a half success."

Market Forecasts Continued Volatility… Medium- to Long-Term Variables Remain

The market is leaning toward the likelihood of continued volatility for the time being. While the negative news of missing the primary endpoint is weighing on short-term investor sentiment, the remaining Phase 3 results and future consultations with regulatory authorities are expected to serve as medium- to long-term variables. Investors' attention is now turning to the 22nd trading session.

[This article is not intended to solicit investment. All final investment decisions and responsibilities lie with the individual investor.]